공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

글루코키나아제(헥소키나아제 D, 헥소키나아제 IV, EC 2.7.1.2) : 파이프라인 리뷰

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 364838
페이지 정보 영문 73 Pages
가격
US $ 3,500 ₩ 4,191,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,382,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,573,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


글루코키나아제(헥소키나아제 D, 헥소키나아제 IV, EC 2.7.1.2) : 파이프라인 리뷰 Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 73 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

글루코키나아제(헥소키나아제 D, 헥소키나아제 IV, EC 2.7.1.2)를 표적으로 한 치료제 개발 상황에 대해 분석했으며, 개발 단계, 약제 표적, 작용기서, 투여 경로 및 분자 종류별 분석, 치료제 개발에 참여하고 있는 기업 개요, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

글루코키나아제(헥소키나아제 D, 헥소키나아제 IV, EC 2.7.1.2) 개요

치료제 개발

글루코키나아제(헥소키나아제 D, 헥소키나아제 IV, EC 2.7.1.2) : 개발중인 제품 - 개발 단계별

글루코키나아제(헥소키나아제 D, 헥소키나아제 IV, EC 2.7.1.2) : 개발중인 제품 - 치료 분야별

글루코키나아제(헥소키나아제 D, 헥소키나아제 IV, EC 2.7.1.2) : 개발중인 제품 - 적응증별

글루코키나아제(헥소키나아제 D, 헥소키나아제 IV, EC 2.7.1.2) : 파이프라인 제품 개요

  • 후기 단계 제품
  • 초기 단계 제품

글루코키나아제(헥소키나아제 D, 헥소키나아제 IV, EC 2.7.1.2) : 기업에서 개발중인 제품

글루코키나아제(헥소키나아제 D, 헥소키나아제 IV, EC 2.7.1.2) : 치료제 평가

  • 단독요법/병용요법 제품별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

글루코키나아제(헥소키나아제 D, 헥소키나아제 IV, EC 2.7.1.2) 치료제 개발에 참여하고 있는 기업

  • Advinus Therapeutics Ltd
  • Amgen Inc.
  • Hua Medicine(Shanghai) Ltd.
  • LG Life Science LTD.
  • Ligand Pharmaceuticals, Inc.
  • Novartis AG
  • Poxel SA
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited
  • vTv Therapeutics Inc
  • Yuhan Corporation

약제 개요

글루코키나아제(헥소키나아제 D, 헥소키나아제 IV, EC 2.7.1.2) : 휴지중인 프로젝트

글루코키나아제(헥소키나아제 D, 헥소키나아제 IV, EC 2.7.1.2) : 개발이 중지된 제품

글루코키나아제(헥소키나아제 D, 헥소키나아제 IV, EC 2.7.1.2) : 주요 뉴스와 프레스 릴리스

부록

KSM 16.08.10

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Eli Lilly and Co, 2021
  • Pipeline by Hua Medicine Shanghai Ltd, 2021
  • Pipeline by Impetis Biosciences Ltd, 2021
  • Pipeline by Kriya Therapeutics Inc, 2021
  • Pipeline by Ligand Pharmaceuticals Inc, 2021
  • Pipeline by Merck & Co Inc, 2021
  • Pipeline by Pfizer Inc, 2021
  • Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, 2021
  • Pipeline by vTv Therapeutics Inc, 2021
  • Dormant Projects, 2021
  • Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Glucokinase - Drugs In Development, 2021, outlays comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage. The molecules developed by companies in Pre-Registration, Phase II and Preclinical stages are 1, 4 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Type 2 Diabetes, Type 1 Diabetes (Juvenile Diabetes), Diabetes and Obesity.

Furthermore, this report also reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)
  • The report reviews Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Overview
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Companies Involved in Therapeutics Development
  • Eli Lilly and Co
  • Hua Medicine Shanghai Ltd
  • Impetis Biosciences Ltd
  • Kriya Therapeutics Inc
  • Ligand Pharmaceuticals Inc
  • Merck & Co Inc
  • Pfizer Inc
  • Sanwa Kagaku Kenkyusho Co Ltd
  • vTv Therapeutics Inc
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drug Profiles
  • dorzagliatin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate Glucokinase and Insulin for Diabetes and Obesity - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GKM-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KTA-112 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-2608204 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-04937319 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules 1 to Activate Glucokinase for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate Glucokinase for Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TTP-399 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Dormant Products
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Discontinued Products
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Product Development Milestones
  • Featured News & Press Releases
  • Apr 23, 2021: Hua Medicine announces acceptance of a New Drug Application for Dorzagliatin in China - First glucokinase activator (GKA) globally
  • Apr 13, 2021: vTv Therapeutics receives FDA breakthrough therapy designation for TTP399 for the treatment of type 1 diabetes
  • Apr 12, 2021: TTP399 SimpliciT-1 study results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin
  • Mar 23, 2021: vTv Therapeutics announces issuance of U.S. patent covering methods of treatment using TTP399
  • Mar 19, 2021: Milestone development achieved in clinical trials and commercialization, Hua medicine's dorzagliatin readying for NDA submission
  • Mar 18, 2021: vTv Therapeutics announces initiation of study evaluating TTP399's potential to reduce risk of diabetic ketoacidosis in patients with type 1 diabetes
  • Feb 23, 2021: vTv Therapeutics announces publication in diabetes care of results from SimpliciT-1 study of TTP399 in patients with type 1 diabetes
  • Dec 18, 2020: Hua Medicine successfully completed the Phase III registration clinical study and announced the 52-week results of the DAWN study (HMM0302) of the combined use of dozaglietin and metformin
  • Oct 14, 2020: Hua Medicine announces the drug manufacturing permit granted for Dorzagliatin
  • Sep 16, 2020: vTv Therapeutics to present additional positive clinical study results from phase 2 Simplici-T1 study of TTP399 as adjunctive therapy for patients with type 1 diabetes at EASD Virtual Meeting
  • Jul 01, 2020: Hua Medicine announces positive 24-week topline results of phase III metformin combination trial of dorzagliatin
  • Jun 18, 2020: Hua Medicine successfully completes SEED (HMM0301), Dorzagliatin's phase III Monotherapy trial
  • Jun 15, 2020: Hua Medicine's Dorzagliatin demonstrates improvements in B-Cell function in data presented at the American Diabetes Association's 80th Scientific Sessions
  • Jun 13, 2020: vTv Therapeutics presents two late-breaking poster sessions on Simplici-T1 study at the American Diabetes Association's Virtual Sessions supporting the potential of TTP399 as first-in-class oral adjunctive therapy for Type 1 Diabetes patients
  • May 31, 2020: Hua Medicine selected for inclusion in the MSCI Hong Kong Micro Cap Index
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q